The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study is published in the May 2025 issue of Chronic ...

Add Yahoo as a preferred source to see more of our stories on Google. Few situations are more unsettling than not being able to breathe. Whether from a momentary injury that knocks the wind out of you ...

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that obstructs airflow and makes breathing difficult. It encompasses several respiratory conditions, including chronic ...

Add Yahoo as a preferred source to see more of our stories on Google. Chronic obstructive pulmonary disease (COPD) is a lung condition that often hides in plain sight. You may think you’re dealing ...

March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...

Few situations are more unsettling than not being able to breathe. Whether from a momentary injury that knocks the wind out of you, swimming underwater for too long or recovering after sprinting at ...